Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

Fragile X, Rett, PD, PDD, and schizophrenia are early stage programs that are going nowhere fast. It’ll take many years, many tens of millions of dollars, and a rebuilding of diverse in-house expertise to advance those programs toward regulatory review. Where is the money going to come from? Just as importantly, how much dilution will that represent?

I hate being a Negative Nelly but I just don’t see a realistic way forward except an all-stock merger with a stronger company.

If it were me, I’d be quietly speaking with biotech investment bankers to find the best deal I could get.